Summit Therapeutics plc
("Summit" or the "Company")
EXERCISE OF SHARE OPTIONS
Oxford, UK, 28 June 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug
discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile
infection, announces that, following the exercise of employee share options, the Company has today issued 16,667 new ordinary
shares of 1p each (the "New Ordinary Shares").
Application has been made for the admission to trading on AIM of the New Ordinary Shares, which will rank pari
passu with the Company's existing ordinary shares, and admission is expected to occur on or around 4 July 2016.
Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting
rights in issue will be 61,484,452. This figure may be used by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's
Disclosure and Transparency Rules.
- END -
For more information, please contact:
Summit Therapeutics
Richard Pye (UK office)
Erik Ostrowski (US office)
|
Tel: +44 (0)1235 443 951
+1 617 294 6607 |
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson
|
Tel: +44 (0)20 7148 7900 |
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions
clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Summit Therapeutics plc via Globenewswire
HUG#2023666